Read on Twitter
A Psychedelic Opportunity
1/9
As we emerge from this global #pandemic, #anxiety, #depression, and alcohol & opioid #addiction will prove to be some of the most pressing issues in society.
1/9
As we emerge from this global #pandemic, #anxiety, #depression, and alcohol & opioid #addiction will prove to be some of the most pressing issues in society.
2/9
#Psychedelic substances are showing great promise to resolve these issues, and unlike the #cannabis industry, companies in the space are choosing to ignore the recreational market, setting their sights solely on approval via the #FDA pathway.
#Psychedelic substances are showing great promise to resolve these issues, and unlike the #cannabis industry, companies in the space are choosing to ignore the recreational market, setting their sights solely on approval via the #FDA pathway.
3/9
Psychedelic medicines are truly one of a kind, in that there is a tremendous amount of positive anecdotal evidence prior to even the first clinical trials.
Psychedelic medicines are truly one of a kind, in that there is a tremendous amount of positive anecdotal evidence prior to even the first clinical trials.
4/9
This anecdotal evidence includes #SiliconValley software engineers micro-dosing #LSD or #Psilocybin for productivity purposes & individuals who& #39;ve struggled with anxiety & depression that’ve found relief &/or enjoy the experience and associated healing properties.
This anecdotal evidence includes #SiliconValley software engineers micro-dosing #LSD or #Psilocybin for productivity purposes & individuals who& #39;ve struggled with anxiety & depression that’ve found relief &/or enjoy the experience and associated healing properties.
6/9
I don’t think the market currently understands the value $MMEDF holds.
3 Key Areas of Value:
1-A Diverse Portfolio of Clinical Trials
2-Partnerships with:
Univ. Hosp. Basel Liechti Lab &
@nyulangone @nyugrossman
3-Extensive Pharmaceutical Experience of Management
I don’t think the market currently understands the value $MMEDF holds.
3 Key Areas of Value:
1-A Diverse Portfolio of Clinical Trials
2-Partnerships with:
Univ. Hosp. Basel Liechti Lab &
@nyulangone @nyugrossman
3-Extensive Pharmaceutical Experience of Management
7/9
MindMed Clinical Trials
MindMed Clinical Trials
8/9
Companies like $MMEDF are not looking to patent these medicines directly, instead they intend to develop IP around them.
$MMEDF has developed Hallucinogenic & Non-Hallucinogenic Therapies, as well as an LSD Neutralizer that can shorten and stop LSD trips.
Companies like $MMEDF are not looking to patent these medicines directly, instead they intend to develop IP around them.
$MMEDF has developed Hallucinogenic & Non-Hallucinogenic Therapies, as well as an LSD Neutralizer that can shorten and stop LSD trips.
9/9
$MMEDF which trades on the NEO & OTC, has recently applied for a NASDAQ Uplisting, appointing @CanaccorGenuity as Financial Advisor.
$MMEDF which trades on the NEO & OTC, has recently applied for a NASDAQ Uplisting, appointing @CanaccorGenuity as Financial Advisor.
